Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Neuroendocrine Tumors Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Neuroendocrine Tumors Overview | 13 | 1 |
| Pipeline Products for Neuroendocrine Tumors Comparative Analysis | 14 | 1 |
| Neuroendocrine Tumors Therapeutics under Development by Companies | 15 | 2 |
| Neuroendocrine Tumors Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Neuroendocrine Tumors Pipeline Products Glance | 18 | 3 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Neuroendocrine Tumors Products under Development by Companies | 21 | 3 |
| Neuroendocrine Tumors Products under Investigation by Universities/Institutes | 24 | 1 |
| Neuroendocrine Tumors Companies Involved in Therapeutics Development | 25 | 35 |
| Advanced Accelerator Applications S.A. | 25 | 1 |
| Aegis Therapeutics, LLC | 26 | 1 |
| Amgen Inc. | 27 | 1 |
| AVEO Pharmaceuticals, Inc. | 28 | 1 |
| Boehringer Ingelheim GmbH | 29 | 1 |
| Chiasma, Inc. | 30 | 1 |
| Crinetics Pharmaceuticals, Inc. | 31 | 1 |
| Daiichi Sankyo Company, Limited | 32 | 1 |
| Delcath Systems, Inc. | 33 | 1 |
| DexTech Medical AB | 34 | 1 |
| Eisai Co., Ltd. | 35 | 1 |
| Exelixis, Inc. | 36 | 1 |
| Foresee Pharmaceuticals, LLC | 37 | 1 |
| Hutchison MediPharma Limited | 38 | 1 |
| Intezyne, Inc | 39 | 1 |
| INVENT Pharmaceuticals, Inc. | 40 | 1 |
| Ipsen S.A. | 41 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 42 | 1 |
| Karyopharm Therapeutics, Inc. | 43 | 1 |
| Lexicon Pharmaceuticals, Inc. | 44 | 1 |
| Midatech Pharma Plc | 45 | 1 |
| Millennium Pharmaceuticals, Inc. | 46 | 1 |
| MolMed S.p.A. | 47 | 1 |
| Northwest Biotherapeutics, Inc. | 48 | 1 |
| Novartis AG | 49 | 1 |
| OctreoPharm Sciences GmbH | 50 | 1 |
| OXiGENE, Inc. | 51 | 1 |
| Peptron, Inc. | 52 | 1 |
| Pfizer Inc. | 53 | 1 |
| Pharma Mar, S.A. | 54 | 1 |
| Progenics Pharmaceuticals, Inc. | 55 | 1 |
| Provectus Biopharmaceuticals, Inc. | 56 | 1 |
| Sompharmaceuticals S.A. | 57 | 1 |
| Strongbridge Biopharma plc | 58 | 1 |
| Vascular Biogenics Ltd. | 59 | 1 |
| Neuroendocrine Tumors Therapeutics Assessment | 60 | 12 |
| Assessment by Monotherapy Products | 60 | 1 |
| Assessment by Target | 61 | 4 |
| Assessment by Mechanism of Action | 65 | 3 |
| Assessment by Route of Administration | 68 | 2 |
| Assessment by Molecule Type | 70 | 2 |
| Drug Profiles | 72 | 120 |
| AV-203 - Drug Profile | 72 | 1 |
| Product Description | 72 | 1 |
| Mechanism of Action | 72 | 1 |
| R&D Progress | 72 | 2 |
| axitinib - Drug Profile | 74 | 1 |
| Product Description | 74 | 1 |
| Mechanism of Action | 74 | 1 |
| R&D Progress | 74 | 4 |
| cabozantinib s-malate - Drug Profile | 78 | 1 |
| Product Description | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| R&D Progress | 78 | 5 |
| COR-005 - Drug Profile | 83 | 1 |
| Product Description | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| R&D Progress | 83 | 3 |
| DCVax-Direct - Drug Profile | 86 | 1 |
| Product Description | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| R&D Progress | 86 | 1 |
| DS-6051 - Drug Profile | 87 | 1 |
| Product Description | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| R&D Progress | 87 | 1 |
| E-7449 - Drug Profile | 88 | 1 |
| Product Description | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| R&D Progress | 88 | 1 |
| Edotreotide Labeled Yttrium 90 - Drug Profile | 89 | 1 |
| Product Description | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| R&D Progress | 89 | 2 |
| everolimus - Drug Profile | 91 | 1 |
| Product Description | 91 | 1 |
| Mechanism of Action | 91 | 1 |
| R&D Progress | 91 | 7 |
| fosbretabulin tromethamine - Drug Profile | 98 | 1 |
| Product Description | 98 | 1 |
| Mechanism of Action | 98 | 1 |
| R&D Progress | 98 | 4 |
| FP-002 - Drug Profile | 102 | 1 |
| Product Description | 102 | 1 |
| Mechanism of Action | 102 | 1 |
| R&D Progress | 102 | 1 |
| G-02113 - Drug Profile | 103 | 1 |
| Product Description | 103 | 1 |
| Mechanism of Action | 103 | 1 |
| R&D Progress | 103 | 1 |
| ganitumab - Drug Profile | 104 | 1 |
| Product Description | 104 | 1 |
| Mechanism of Action | 104 | 1 |
| R&D Progress | 104 | 3 |
| HMPL-012 - Drug Profile | 107 | 1 |
| Product Description | 107 | 1 |
| Mechanism of Action | 107 | 1 |
| R&D Progress | 107 | 2 |
| INV-440 - Drug Profile | 109 | 1 |
| Product Description | 109 | 1 |
| Mechanism of Action | 109 | 1 |
| R&D Progress | 109 | 1 |
| iobenguane sulfate I 131 - Drug Profile | 110 | 1 |
| Product Description | 110 | 1 |
| Mechanism of Action | 110 | 1 |
| R&D Progress | 110 | 2 |
| IT-139 - Drug Profile | 112 | 1 |
| Product Description | 112 | 1 |
| Mechanism of Action | 112 | 1 |
| R&D Progress | 112 | 1 |
| L-779976 - Drug Profile | 113 | 1 |
| Product Description | 113 | 1 |
| Mechanism of Action | 113 | 1 |
| R&D Progress | 113 | 2 |
| lanreotide acetate - Drug Profile | 115 | 1 |
| Product Description | 115 | 1 |
| Mechanism of Action | 115 | 1 |
| R&D Progress | 115 | 2 |
| lurbinectedin - Drug Profile | 117 | 1 |
| Product Description | 117 | 1 |
| Mechanism of Action | 117 | 1 |
| R&D Progress | 117 | 4 |
| Lutathera - Drug Profile | 121 | 1 |
| Product Description | 121 | 1 |
| Mechanism of Action | 121 | 1 |
| R&D Progress | 121 | 3 |
| lutetium (177Lu) edotreotide - Drug Profile | 124 | 1 |
| Product Description | 124 | 1 |
| Mechanism of Action | 124 | 1 |
| R&D Progress | 124 | 1 |
| melphalan - Drug Profile | 125 | 1 |
| Product Description | 125 | 1 |
| Mechanism of Action | 125 | 1 |
| R&D Progress | 125 | 3 |
| netazepide - Drug Profile | 128 | 1 |
| Product Description | 128 | 1 |
| Mechanism of Action | 128 | 1 |
| R&D Progress | 128 | 2 |
| NGR-hTNF - Drug Profile | 130 | 1 |
| Product Description | 130 | 1 |
| Mechanism of Action | 130 | 1 |
| R&D Progress | 130 | 4 |
| nintedanib - Drug Profile | 134 | 1 |
| Product Description | 134 | 1 |
| Mechanism of Action | 134 | 1 |
| R&D Progress | 134 | 6 |
| Novaferon - Drug Profile | 140 | 1 |
| Product Description | 140 | 1 |
| Mechanism of Action | 140 | 1 |
| R&D Progress | 140 | 2 |
| octreotide acetate - Drug Profile | 142 | 1 |
| Product Description | 142 | 1 |
| Mechanism of Action | 142 | 1 |
| R&D Progress | 142 | 3 |
| octreotide acetate - Drug Profile | 145 | 1 |
| Product Description | 145 | 1 |
| Mechanism of Action | 145 | 1 |
| R&D Progress | 145 | 1 |
| octreotide acetate long acting - Drug Profile | 146 | 1 |
| Product Description | 146 | 1 |
| Mechanism of Action | 146 | 1 |
| R&D Progress | 146 | 2 |
| octreotide acetate SR - Drug Profile | 148 | 1 |
| Product Description | 148 | 1 |
| Mechanism of Action | 148 | 1 |
| R&D Progress | 148 | 1 |
| octreotide SR - Drug Profile | 149 | 1 |
| Product Description | 149 | 1 |
| Mechanism of Action | 149 | 1 |
| R&D Progress | 149 | 1 |
| ofranergene obadenovec - Drug Profile | 150 | 1 |
| Product Description | 150 | 1 |
| Mechanism of Action | 150 | 1 |
| R&D Progress | 150 | 2 |
| OPS-201 - Drug Profile | 152 | 1 |
| Product Description | 152 | 1 |
| Mechanism of Action | 152 | 1 |
| R&D Progress | 152 | 1 |
| panobinostat - Drug Profile | 153 | 1 |
| Product Description | 153 | 1 |
| Mechanism of Action | 153 | 1 |
| R&D Progress | 153 | 7 |
| PV-10 - Drug Profile | 160 | 1 |
| Product Description | 160 | 1 |
| Mechanism of Action | 160 | 1 |
| R&D Progress | 160 | 5 |
| ribociclib succinate - Drug Profile | 165 | 1 |
| Product Description | 165 | 1 |
| Mechanism of Action | 165 | 1 |
| R&D Progress | 165 | 3 |
| RRX-001 - Drug Profile | 168 | 1 |
| Product Description | 168 | 1 |
| Mechanism of Action | 168 | 1 |
| R&D Progress | 168 | 2 |
| rSIFN-co - Drug Profile | 170 | 1 |
| Product Description | 170 | 1 |
| Mechanism of Action | 170 | 1 |
| R&D Progress | 170 | 1 |
| sapanisertib - Drug Profile | 171 | 1 |
| Product Description | 171 | 1 |
| Mechanism of Action | 171 | 1 |
| R&D Progress | 171 | 2 |
| selinexor - Drug Profile | 173 | 1 |
| Product Description | 173 | 1 |
| Mechanism of Action | 173 | 1 |
| R&D Progress | 173 | 6 |
| SHR-1020 - Drug Profile | 179 | 1 |
| Product Description | 179 | 1 |
| Mechanism of Action | 179 | 1 |
| R&D Progress | 179 | 2 |
| Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile | 181 | 1 |
| Product Description | 181 | 1 |
| Mechanism of Action | 181 | 1 |
| R&D Progress | 181 | 1 |
| Somadex - Drug Profile | 182 | 1 |
| Product Description | 182 | 1 |
| Mechanism of Action | 182 | 1 |
| R&D Progress | 182 | 1 |
| sunitinib malate - Drug Profile | 183 | 1 |
| Product Description | 183 | 1 |
| Mechanism of Action | 183 | 1 |
| R&D Progress | 183 | 5 |
| Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors - Drug Profile | 188 | 1 |
| Product Description | 188 | 1 |
| Mechanism of Action | 188 | 1 |
| R&D Progress | 188 | 1 |
| telotristat etiprate - Drug Profile | 189 | 1 |
| Product Description | 189 | 1 |
| Mechanism of Action | 189 | 1 |
| R&D Progress | 189 | 2 |
| TR-2A - Drug Profile | 191 | 1 |
| Product Description | 191 | 1 |